Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes.
Publication/Presentation Date
10-1-2020
Abstract
The use of cyclophosphamide (CY) for bidirectional tolerization of recipient and donor T cells is associated with reduced rates of graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) after HLA-matched hematopoietic stem cell transplantation (HSCT). However, recurrent disease remains the primary barrier to long-term survival. We extended our 2-step approach to HLA-matched related HSCT using a radiation-based myeloablative conditioning regimen combined with a high dose of T cells in an attempt to reduce relapse rates while maintaining the beneficial effects of CY tolerization. After conditioning, patients received their grafts in 2 components: (1) a fixed dose of 2 × 10
Volume
26
Issue
10
First Page
1861
Last Page
1867
ISSN
1523-6536
Published In/Presented At
Grosso, D., Carabasi, M., Filicko-O'Hara, J., Wagner, J. L., O'Hara, W., Sun, M., Colombe, B., Shi, W., Werner-Wasik, M., Rudolph, S., Alpdogan, O., Binder, A., Kasner, M., Klumpp, T., Martinez-Outschoorn, U., Palmisiano, N., Wilde, L., Porcu, P., Gergis, U., & Flomenberg, N. (2020). Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(10), 1861–1867. https://doi.org/10.1016/j.bbmt.2020.06.021
Disciplines
Medicine and Health Sciences
PubMedID
32629157
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article